Avalo Therapeutics (AVTX) Competitors $4.41 -0.22 (-4.75%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$4.42 +0.00 (+0.11%) As of 04/17/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVTX vs. MNPR, NVCT, LFCR, YMAB, SLRN, IMMP, PROK, HUMA, ITOS, and SLDBShould you be buying Avalo Therapeutics stock or one of its competitors? The main competitors of Avalo Therapeutics include Monopar Therapeutics (MNPR), Nuvectis Pharma (NVCT), Lifecore Biomedical (LFCR), Y-mAbs Therapeutics (YMAB), Acelyrin (SLRN), Immutep (IMMP), ProKidney (PROK), Humacyte (HUMA), iTeos Therapeutics (ITOS), and Solid Biosciences (SLDB). These companies are all part of the "pharmaceutical products" industry. Avalo Therapeutics vs. Monopar Therapeutics Nuvectis Pharma Lifecore Biomedical Y-mAbs Therapeutics Acelyrin Immutep ProKidney Humacyte iTeos Therapeutics Solid Biosciences Avalo Therapeutics (NASDAQ:AVTX) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, analyst recommendations, community ranking, dividends, valuation, earnings and profitability. Which has higher valuation & earnings, AVTX or MNPR? Monopar Therapeutics has lower revenue, but higher earnings than Avalo Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvalo Therapeutics$441K106.72-$31.54MN/AN/AMonopar TherapeuticsN/AN/A-$8.40M-$3.60-11.00 Do analysts prefer AVTX or MNPR? Avalo Therapeutics presently has a consensus target price of $33.00, indicating a potential upside of 648.30%. Monopar Therapeutics has a consensus target price of $55.33, indicating a potential upside of 39.77%. Given Avalo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Avalo Therapeutics is more favorable than Monopar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avalo Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Monopar Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has more risk and volatility, AVTX or MNPR? Avalo Therapeutics has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, Monopar Therapeutics has a beta of 1.01, meaning that its share price is 1% more volatile than the S&P 500. Does the media refer more to AVTX or MNPR? In the previous week, Avalo Therapeutics had 3 more articles in the media than Monopar Therapeutics. MarketBeat recorded 4 mentions for Avalo Therapeutics and 1 mentions for Monopar Therapeutics. Avalo Therapeutics' average media sentiment score of 0.21 beat Monopar Therapeutics' score of 0.00 indicating that Avalo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Monopar Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals have more ownership in AVTX or MNPR? 87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are held by institutional investors. 0.3% of Avalo Therapeutics shares are held by insiders. Comparatively, 34.9% of Monopar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community favor AVTX or MNPR? Monopar Therapeutics received 34 more outperform votes than Avalo Therapeutics when rated by MarketBeat users. Likewise, 73.02% of users gave Monopar Therapeutics an outperform vote while only 48.00% of users gave Avalo Therapeutics an outperform vote. CompanyUnderperformOutperformAvalo TherapeuticsOutperform Votes1248.00% Underperform Votes1352.00% Monopar TherapeuticsOutperform Votes4673.02% Underperform Votes1726.98% Is AVTX or MNPR more profitable? Monopar Therapeutics' return on equity of -107.21% beat Avalo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Avalo TherapeuticsN/A -442.16% 122.99% Monopar Therapeutics N/A -107.21%-87.57% SummaryAvalo Therapeutics beats Monopar Therapeutics on 8 of the 14 factors compared between the two stocks. Get Avalo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVTX vs. The Competition Export to ExcelMetricAvalo TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$47.06M$6.45B$5.30B$7.35BDividend YieldN/A3.23%5.12%4.30%P/E RatioN/A6.8921.8017.80Price / Sales106.72231.03379.9697.74Price / CashN/A65.6738.2634.64Price / Book0.485.936.443.98Net Income-$31.54M$142.99M$3.21B$247.73M7 Day Performance-10.00%4.42%2.87%1.81%1 Month Performance-43.24%-12.73%-8.63%-6.98%1 Year Performance-63.28%-9.48%11.46%1.37% Avalo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVTXAvalo Therapeutics3.3021 of 5 stars$4.41-4.8%$33.00+648.3%-67.6%$47.06M$441,000.000.0040Short Interest ↑MNPRMonopar Therapeutics1.8071 of 5 stars$37.49+7.5%$55.33+47.6%+1,118.2%$229.18MN/A-19.0310Gap UpNVCTNuvectis Pharma2.0821 of 5 stars$9.78+17.7%$15.67+60.2%+31.1%$228.77MN/A-8.438Positive NewsGap UpLFCRLifecore Biomedical1.1386 of 5 stars$6.17+6.0%$8.00+29.7%-1.8%$228.44M$130.86M-11.02690News CoverageGap DownYMABY-mAbs Therapeutics3.5162 of 5 stars$4.93+2.1%$18.30+271.2%-69.0%$222.93M$87.69M-9.13150Short Interest ↓Positive NewsSLRNAcelyrin3.5426 of 5 stars$2.18-2.2%$9.60+340.4%-56.2%$219.98MN/A-0.89135Short Interest ↓Positive NewsIMMPImmutep1.1009 of 5 stars$1.49+2.1%$8.50+470.5%-31.9%$216.88M$5.14M0.002,021Positive NewsPROKProKidney2.4525 of 5 stars$0.74+1.2%$5.00+575.7%-72.2%$216.60M$76,000.00-1.353Insider TradeNews CoveragePositive NewsGap UpHUMAHumacyte2.5518 of 5 stars$1.49-2.6%$13.71+820.4%-46.2%$215.82M$1.57M-1.11150Positive NewsITOSiTeos Therapeutics2.2491 of 5 stars$5.53-2.1%$25.75+365.6%-39.0%$211.21M$35M-1.7690Short Interest ↑SLDBSolid Biosciences3.3487 of 5 stars$2.71+0.4%$15.67+478.1%-74.5%$210.01M$8.09M-0.89100 Related Companies and Tools Related Companies Monopar Therapeutics Competitors Nuvectis Pharma Competitors Lifecore Biomedical Competitors Y-mAbs Therapeutics Competitors Acelyrin Competitors Immutep Competitors ProKidney Competitors Humacyte Competitors iTeos Therapeutics Competitors Solid Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVTX) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | Sponsored2025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisisWhat's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot...Stansberry Research | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AVTX Stock Free AVTX Stock Alerts